Abstract
Various formulations containing titanocene Y (bis-[(p-methoxybenzyl)cyclopentadienyl] titanium (IV) dichloride) were prepared and tested in vitro on CAKI-1 cells in order to compare the cytotoxic behaviour of the compound with different formulation reagents. Formulations were prepared with non-ionic surfactants like Cremophor EL and Tween 80, pegylated reagents PEG-400 and Solutol HS 15, and the co-solvent Soluphor P (pyrrolidone-2). All formulations were tested with and without the presence of dimethylsulfoxide. When the lipophilic derivative titanocene Y was formulated with Soluphor P and tested in vitro, an IC50 value of 10 (+/- 1) μM was observed, which is a 3-fold increase in cytotoxicity when compared to the DMSO formulation. In order to compare to a more hydrophilic titanocene this Soluphor P formulation method was extended to the water-soluble titanocene G, which is a dihydrochloride derivative of bis-[(1-methyl- 3-dimethylaminomethylindol-2-yl)cyclopentadienyl] titanium (IV) dichloride). When titanocene G was tested in vitro in the presence of Soluphor P, it resulted in a 10-fold increase in cytotoxicity with an IC50 value of 0.71 (+/- 0.24) ?μM against CAKI-1 cells.
Keywords: Titanocene Y, Formulation, CAKI-1 cells, Cremophor EL, Tween 80, PEG-400, Solutol HS 15, Soluphor P, Solubility, Cytotoxicity, MTT assay
Letters in Drug Design & Discovery
Title: The Cytotoxicity of Titanocene Y Against CAKI-1 Cells: An In Vitro Formulation Study
Volume: 7 Issue: 5
Author(s): Megan Hogan, Brendan Gleeson and Matthias Tacke
Affiliation:
Keywords: Titanocene Y, Formulation, CAKI-1 cells, Cremophor EL, Tween 80, PEG-400, Solutol HS 15, Soluphor P, Solubility, Cytotoxicity, MTT assay
Abstract: Various formulations containing titanocene Y (bis-[(p-methoxybenzyl)cyclopentadienyl] titanium (IV) dichloride) were prepared and tested in vitro on CAKI-1 cells in order to compare the cytotoxic behaviour of the compound with different formulation reagents. Formulations were prepared with non-ionic surfactants like Cremophor EL and Tween 80, pegylated reagents PEG-400 and Solutol HS 15, and the co-solvent Soluphor P (pyrrolidone-2). All formulations were tested with and without the presence of dimethylsulfoxide. When the lipophilic derivative titanocene Y was formulated with Soluphor P and tested in vitro, an IC50 value of 10 (+/- 1) μM was observed, which is a 3-fold increase in cytotoxicity when compared to the DMSO formulation. In order to compare to a more hydrophilic titanocene this Soluphor P formulation method was extended to the water-soluble titanocene G, which is a dihydrochloride derivative of bis-[(1-methyl- 3-dimethylaminomethylindol-2-yl)cyclopentadienyl] titanium (IV) dichloride). When titanocene G was tested in vitro in the presence of Soluphor P, it resulted in a 10-fold increase in cytotoxicity with an IC50 value of 0.71 (+/- 0.24) ?μM against CAKI-1 cells.
Export Options
About this article
Cite this article as:
Hogan Megan, Gleeson Brendan and Tacke Matthias, The Cytotoxicity of Titanocene Y Against CAKI-1 Cells: An In Vitro Formulation Study, Letters in Drug Design & Discovery 2010; 7 (5) . https://dx.doi.org/10.2174/157018010791163479
DOI https://dx.doi.org/10.2174/157018010791163479 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets Prevalence and Risk Factors of Vitamin D Deficiency in Critically Ill Patients
Inflammation & Allergy - Drug Targets (Discontinued) Neonatal Systemic Thrombosis: An Updated Overview
Current Vascular Pharmacology Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure
Current Pharmaceutical Design The Effect of Polyphenol Consumption on Blood Pressure
Mini-Reviews in Medicinal Chemistry Neuroprotective Role of Hypothermia in Hypoxic-ischemic Brain Injury: Combined Therapies using Estrogen
Current Neuropharmacology A Mini Review on Biological Activities of Pyridazinone Derivatives as Antiulcer, Antisecretory, antihistamine and Particularly Against Histamine H3R
Mini-Reviews in Medicinal Chemistry Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design Emerging Treatments in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Conformation and Bioactivity. Design and Discovery of Novel Antihypertensive Drugs
Current Topics in Medicinal Chemistry Induction of Cytochrome P450 3A by the Ginkgo biloba Extract and Bilobalides in Human and Rat Primary Hepatocytes
Drug Metabolism Letters Mastering the Treatment of Diabetes Mellitus Type 1 in Childhood and Adolescence
Current Pediatric Reviews The Evolution of Clostridium difficile Infection in Cancer Patients: Epidemiology, Pathophysiology, and Guidelines for Prevention and Management
Recent Patents on Anti-Infective Drug Discovery Docking, Synthesis and Anti-Diabetic Activity of Novel Sulfonylhydrazone Derivatives Designed as PPAR-Gamma Agonists
Current Topics in Medicinal Chemistry Exploring Nanotechnologies for the Effective Therapy of Malaria Using Plant-Based Medicines
Current Pharmaceutical Design The Possible Adverse Effects of Intramuscular Botulinum Toxin Injections and their Management
Current Drug Safety Diabetes Mellitus during the Pandemic Covid-19: Prevalence, Pathophysiology, Mechanism, and Management: An updated overview
Current Diabetes Reviews A Fatal Case of Acute Interstitial Pneumonia (AIP) in a Woman Affected by Glioblastoma
Current Drug Safety Prevention of Contrast Induced Nephropathy
Current Drug Therapy